echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Up to about 1.08 billion yuan, Fuhong Henlius won the right of a BRAF inhibitor from Runxin Biotech

    Up to about 1.08 billion yuan, Fuhong Henlius won the right of a BRAF inhibitor from Runxin Biotech

    • Last Update: 2021-04-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Source: Immediate Medicine News

    On March 29, 2021, Henlius Fuhong announced that it has reached an exclusive license cooperation with Runxin Bio for the BRAF V600E inhibitor RX208.


    BRAF protein is an important upstream regulator in the MAPK/ERK signaling pathway.


    The BRAF target product RX208 of this cooperation has a brand-new chemical mother nucleus structure and is clinically intended to be used for the treatment of locally advanced or metastatic solid tumors that are positive for BRAF V600E mutations and are not suitable for surgery.


    Note: The original text has been deleted

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.